{
  "round": 4,
  "request": {
    "reason": "大部分假设缺乏机制连通性且面临高风险冲突，可通过补链提升 path_disjointness。",
    "n": 4
  },
  "prev_hypotheses": [
    "Eculizumab",
    "Ravulizumab",
    "C5 Inhibitors",
    "Complement Inhibitors",
    "Fostamatinib",
    "Luspatercept",
    "Dexamethasone",
    "Cyclosporine",
    "Tacrolimus",
    "Sirolimus",
    "Rituximab",
    "Thrombopoietin receptor agonists"
  ],
  "status": "regenerated",
  "generated_seeds": [
    "Eculizumab",
    "Ravulizumab",
    "Avacopan",
    "Furosemide",
    "Amlodipine",
    "Steroids",
    "Angiotensin II receptor blockers",
    "Rasburicase",
    "Caplacizumab",
    "Sirolimus",
    "Defibrotide",
    "Corticosteroids"
  ],
  "new_hypotheses": [
    "Eculizumab",
    "Ravulizumab",
    "Avacopan",
    "Furosemide",
    "Amlodipine",
    "Steroids",
    "Angiotensin II receptor blockers",
    "Rasburicase",
    "Caplacizumab",
    "Sirolimus",
    "Defibrotide",
    "Corticosteroids"
  ]
}